ClinicalTrials.gg

Graft vs Host Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 804 studies for Graft vs Host Disease across more than 10 countries. 148 are recruiting or about to start. 552 of them are mainly about Graft vs Host Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its narrower condition Bronchiolitis Obliterans Syndrome too: 1,472 studies, 263 open.

ClinicalTrials.gov finds 1,701 studies for Graft vs Host Disease. How that becomes 804 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Graft vs Host Disease, and those it files under no condition that list Graft vs Host Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,701Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −667Filed under a narrower condition, counted on its own pageBronchiolitis Obliterans Syndrome 661
  3. −21List Graft vs Host Disease as a condition, but the registry did not file them under itMost often written as “Acute Graft Versus Host Disease” (4), “Graft Versus Host Disease in Eye” (4), and “Ocular Graft vs Host Disease” (2). The registry filed them under other conditions only, most often Dry Eye Syndromes (6) and Hematologic Neoplasms (5).
  4. −209Match it another way186 name it in the title, 11 in a keyword, and 12 by a synonym or other text the search reads.
  5. 804The count on this page110 of them list Graft vs Host Disease in their own words; the registry filed them under no condition.

Status

Completed
375
Terminated
113
Recruiting
102
Status unknown
85
Active, not recruiting
39
Not yet recruiting
36

Phase

Phase 2
375
Phase 1
208
Phase 3
97
Phase 4
24
Early Phase 1
15

Where

United States
454
China
81
France
54
Germany
53
Italy
53
Canada
40

Who develops what

Add Graft vs Host Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 10 programs from 10 companies, 8 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Mesoblast and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Mycophenolic AcidRecent, repeated
Evidence
  • NCT06682169 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Mycophenolate mofetil” · registered Nov 2024
  • NCT06615050 · Incyte Corporation · Phase 3 · live · comparator · “Mycophenolate mofetil (MMF)” · registered Sep 2024
  • NCT03112603 · Incyte Corporation · Phase 3 · comparator · “Mycophenolate mofetil (MMF)” · registered Apr 2017
  • NCT00195273 · Pfizer · Phase 3 · background · “mycophenolate mofetil” · registered Sep 2005
  • NCT00136903 · Mesoblast Limited · Phase 2 · background · “Mycophenolate Mofetil” · registered Aug 2005
Novartis45% of its industry studiesUS: off-patent, 37 generics marketedEU: off-patent, 3 generics authorized22 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
d-MAPPS™ Ophthalmic Solution☆ Track1 live phase-3 study: NCT07776210Regenerative Ocular Immunobiologics LLC
remestemcel-l☆ Track1 live phase-3 study: NCT07568535Mesoblast Limited

The 2 in phase 3 with the nearest primary completion, of 10 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.rhPRG4 450ug/ml · Lubris Bio Pty Ltd · Phase 2 named, not the main aimNCT07118254 A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) — primary endpoint: To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment · 15 enrolled
  • 31 Mar 2027 est.d-MAPPS™ Ophthalmic Solution · Regenerative Ocular Immunobiologics LLC · Phase 3 main aimNCT07776210 Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) — primary endpoint: Change From Baseline to Day 90 in Modified Oxford Corneal Staining Score · 30 enrolled
  • Nov 2027 est.Partially Engineered T-regulatory Cell Donor Graft TRGFT-201 · Orca Biosystems, Inc. · Phase 2 registry mapping onlyNCT07216443 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — primary endpoint: RIC Cohort: GVHD-free and relapse-free survival (GRFS) · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Graft vs Host Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 14 open · Tyrosine kinase inhibitors (TKIs) 14 open · JAK inhibitors 13 open · Antimetabolites 4 open · Calcineurin inhibitors 3 open

Coming up

45studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger. 42 (41%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 9 (9%) take healthy volunteers.

Recruiting studies that take each age, of 102
AgeWomenMen
1030 (29%)30 (29%)
1898 (96%)97 (95%)
3095 (93%)94 (92%)
4094 (92%)93 (91%)
5094 (92%)93 (91%)
6589 (87%)88 (86%)
7570 (69%)70 (69%)
8559 (58%)59 (58%)

Across all 804 studies, recruiting or not: 43% stop at 75 or younger and 26% at 65; 42% take children; <1% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Graft vs Host Disease studies take

Of 103 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 52 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo24–65 · 49 studies—49 mo28–69 · 39 studies
Phase 1/255 mo35–76 · 39 studies——
Phase 252 mo29–87 · 103 studies—55 mo38–116 · 86 studies
Phase 334 mo24–48 · 31 studies——
Interventional, no phase41 mo23–89 · 32 studies——
Observational60 mo37–154 · 46 studies—60 mo38–154 · 45 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 804. Browse all 804 → or search them.